Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor

CONCLUSION: The presence of sarcopenia or myosteatosis is a reliable predictor of the clinical outcomes of patients with GC who are undergoing treatment with an ICI.PMID:38516238 | PMC:PMC10950641 | DOI:10.3748/wjg.v30.i8.863

Source: World Journal of Gastroenterology - March 22, 2024 Category: Gastroenterology Authors: Gui-Ming Deng Hai-Bin Song Zhong-Ze Du Ying-Wei Xue Hong-Jiang Song Yuan-Zhou Li Source Type: research